Approval Applications Planned in Europe and South Korea Within Three Months

Celltrion announced on February 2 that it has completed the approval clinical trial for HerzumaSC, the subcutaneous (SC) formulation of its breast cancer treatment Herzuma (ingredient name: trastuzumab). The company plans to apply for product approval in both Europe and South Korea within three months.

Celltrion logo image. Celltrion

Celltrion logo image. Celltrion

View original image

In this clinical trial, Celltrion directly compared HerzumaSC with the original trastuzumab SC formulation and demonstrated pharmacokinetic (PK) equivalence. There were no significant differences in safety or immunogenicity. Celltrion stated that, following prior consultation, it will be able to apply for approval without the need for additional clinical trials.


HerzumaSC is designed to allow high-dose administration via subcutaneous injection by incorporating hyaluronidase. While the existing intravenous (IV) formulation required approximately 90 minutes for administration, the company expects the SC formulation to reduce this to about five minutes or less.


Europe and South Korea are the main markets for Celltrion's SC formulation products. According to pharmaceutical market research firm IQVIA, the global trastuzumab market was valued at approximately $3.56 billion (about 5.1691 trillion won) as of 2024.


Celltrion explained that with HerzumaSC, it has established a system encompassing the development, approval, production, and sales of SC formulation products. Having already accumulated commercialization experience with RemsimaSC, the company added that it is considering applying the SC formulation to other biosimilars and new drugs in the future.


The company also plans to expand into formulation modification contract manufacturing (CMO) business by providing its SC formulation technology to external pharmaceutical companies.



A Celltrion representative stated, "Starting with the approval application for HerzumaSC, we plan to expand our portfolio of SC formulation products."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing